KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Non Operating Income (2016 - 2025)

Boston Scientific (BSX) has disclosed Non Operating Income for 17 consecutive years, with -$125.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 38.89% to -$125.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$229.0 million through Dec 2025, up 28.88% year-over-year, with the annual reading at -$228.0 million for FY2025, 28.97% up from the prior year.
  • Non Operating Income hit -$125.0 million in Q4 2025 for Boston Scientific, down from -$110.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $181.0 million in Q3 2021 to a low of -$310.0 million in Q1 2022.
  • Historically, Non Operating Income has averaged -$46.8 million across 5 years, with a median of -$58.0 million in 2022.
  • Biggest five-year swings in Non Operating Income: tumbled 1216.67% in 2023 and later skyrocketed 222.0% in 2025.
  • Year by year, Non Operating Income stood at $26.0 million in 2021, then tumbled by 123.08% to -$6.0 million in 2022, then crashed by 1216.67% to -$79.0 million in 2023, then decreased by 13.92% to -$90.0 million in 2024, then crashed by 38.89% to -$125.0 million in 2025.
  • Business Quant data shows Non Operating Income for BSX at -$125.0 million in Q4 2025, -$110.0 million in Q3 2025, and $122.0 million in Q2 2025.